5.18 A Prospective Open-Label Trial of Extended-Release Liquid Methylphenidate for the Treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in Adults With High-Functioning Autism Spectrum Disorder: An Interim Analysis

Gagan Joshi,Barbora Hoskova,Maura Fitzgerald,Tolga Atilla Ceranoglu,Amy Yule,Ronna S. Fried,Maribel Galdo, Abigail H. Belser,Haley Tornberg,Joseph Biederman

JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY（2017）

引用 0|浏览7

暂无评分

摘要

Treating ADHD comorbid with autism spectrum disorder (ASD) could improve morbidity and impairment in individuals with autism; however, lower tolerability to psychotropic medications, used to treat ADHD, has been noted in individuals with ASD. The purpose of this interim analysis of the ongoing six-week trial was to assess the tolerability and efficacy of extended-release liquid methylphenidate hydrochloride (brand name Quillivant) for the treatment of ADHD in adults with high-functioning ASD.

查看译文

关键词

methylphenidate,adhd,deficit/hyperactivity disorder,open-label,extended-release,high-functioning

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要